Does UiPath’s new Agentic AI product and AIUC-1 certification require action from UiPath (PATH) investors?

• UiPath, Inc. recently launched an agent AI automation solution for healthcare revenue cycle management and financial crime compliance, while also achieving AIUC-1 certification for secure AI agents.
• The launch and certification of these products comes on the heels of UiPath’s Q4 2026 financial results, with all eyes on how AI-driven automation will impact the company’s long-term growth profile.
• Here, we explore how UiPath’s healthcare-focused agent AI launch could impact the company’s broader investment story and long-term business outlook.

Take advantage of the AI ​​infrastructure supercycle with our “handpicked selection” of the best 35 AI gold rushes that transform record demand into massive cash flows.

UiPath investment story summary

To own UiPath, you generally need to believe that its end-to-end automation platform can remain relevant as AI-driven workflows become more complex, and that revenue growth and profits can remain resilient despite macro headwinds and intense software competition. While the launch of Healthcare Agent AI and AIUC 1 certification may support this view, near-term drivers remain against Q4 2026 guidance, and the primary risk is that Agent products contribute less to fiscal 2026 revenue than investors expect.

Of all the recent announcements, UiPath’s new healthcare agent AI suite seems to be the most relevant. This is to tie the broader automation story into specific regulated areas where customers often prioritize secure and compliant solutions. With the stock under pressure and the agency not yet clearly driving numbers for fiscal 2026, any evidence that these healthcare products will lead to hiring or higher-value deals could be important in how investors envision the company’s next phase of growth.

But for these opportunities, investors should also focus on how quickly agent AI can move from a promising case study to a meaningful and measurable revenue contribution…

Read the full story on UiPath (it’s free!)

The UiPath story projects revenue of $1.9 billion and revenue of $243.6 million by 2028. This would require an 8.6% increase in annual revenue and an increase in revenue of approximately $311 million from the current -$67.5 million.

We reveal how UiPath’s projections yield a fair value of $15.93, 37% higher than the current price.

explore other perspectives

Fair value estimates for UiPath from the eight Simply Wall Street communities range from approximately US$15.93 to US$21.54 per share, highlighting just how far individual views diverge. You are weighing these opinions against the risk that the new agent AI product may not materially boost revenue in fiscal 2026, which could determine how the market judges execution next quarter.

Check out 8 other fair value estimates on UiPath – see why the stock is worth just $15.93!

decide for yourself

Don’t agree with the existing narrative? Following the herd rarely yields exceptional investment returns. Follow your intuition.

Looking for another opportunity?

First movers are already taking notice. Check out the stocks they are targeting before they leave the shed.

This article by Simply Wall St is general in nature. We provide commentary using only unbiased methodologies, based on historical data and analyst forecasts, and articles are not intended to be financial advice. This is not a recommendation to buy or sell any stock, and does not take into account your objectives or financial situation. We aim to provide long-term, focused analysis based on fundamental data. Note that our analysis may not factor in the latest announcements or qualitative material from price-sensitive companies. Simply Wall St has no position in any stocks mentioned.

Do you have feedback on this article? Interested in its content? Please contact us directly. Alternatively, email editorial-team@simplywallst.com.